SCHEMBL10132081

SCHEMBL10132081

O=C(NCc1ccncc1)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 20/20 0.79
CSNK2B P67870 20/20 0.79
CSNK2A1 P68400 20/20 0.79
CSNK2A3 Q8NEV1 19/20 0.79
CLK2 P49760 7/20 0.79
ALDH1A1 P00352 1/20 0.79
PIM1 P11309 2/20 0.73
PIM2 Q9P1W9 2/20 0.73
CHEK1 O14757 1/20 0.73
GAK O14976 1/20 0.73
DAPK3 O43293 1/20 0.73
DYRK3 O43781 1/20 0.73
ULK1 O75385 1/20 0.73
STK10 O94804 1/20 0.73
CCNB2 O95067 1/20 0.73
CDK1 P06493 1/20 0.73
CCNB1 P14635 1/20 0.73
PHKG2 P15735 1/20 0.73
CCNE1 P24864 1/20 0.73
CDK2 P24941 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132090 0.95 CSNK2A2 (0.78) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL10132101 0.93 CSNK2A2 (0.76) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL28923699 0.88 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL10132086 0.88 CSNK2A2 (0.74) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL2688142 0.88 CSNK2A2 (0.83) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL28644973 0.87 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL10132104 0.87 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL28636359 0.87 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL28923020 0.86 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL28625709 0.86 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A2 810/4885CSNK2B 772/4885CSNK2A1 680/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A2 810/4885CSNK2B 772/4885CSNK2A1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.